GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Return-on-Tangible-Asset

Hansoh Pharmaceutical Group Co (HKSE:03692) Return-on-Tangible-Asset : 12.30% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Hansoh Pharmaceutical Group Co's annualized Net Income for the quarter that ended in Dec. 2023 was HK$4,350 Mil. Hansoh Pharmaceutical Group Co's average total tangible assets for the quarter that ended in Dec. 2023 was HK$35,368 Mil. Therefore, Hansoh Pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 12.30%.

The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset or its related term are showing as below:

HKSE:03692' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 8.65   Med: 15.69   Max: 31.44
Current: 10.32

During the past 8 years, Hansoh Pharmaceutical Group Co's highest Return-on-Tangible-Asset was 31.44%. The lowest was 8.65%. And the median was 15.69%.

HKSE:03692's Return-on-Tangible-Asset is ranked better than
82.07% of 1082 companies
in the Drug Manufacturers industry
Industry Median: 1.84 vs HKSE:03692: 10.32

Hansoh Pharmaceutical Group Co Return-on-Tangible-Asset Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Return-on-Tangible-Asset Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial 18.26 13.12 11.48 8.65 10.33

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.85 9.08 8.54 8.26 12.30

Competitive Comparison of Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset falls into.



Hansoh Pharmaceutical Group Co Return-on-Tangible-Asset Calculation

Hansoh Pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=3584.864/( (33466.217+35943.393)/ 2 )
=3584.864/34704.805
=10.33 %

Hansoh Pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=4350.298/( (34793.56+35943.393)/ 2 )
=4350.298/35368.4765
=12.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data.


Hansoh Pharmaceutical Group Co  (HKSE:03692) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Hansoh Pharmaceutical Group Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Executives
Cen Junda 2307 Founder of a discretionary trust who can infl
Cantrust (far East) Limited 2301 Trustee
Jqc Holding Limited 2201 Interest of corporation controlled by you
Jqc International Limited 2201 Interest of corporation controlled by you
Sun Yuan 2101 Beneficial owner
Harmonia Holding Investing (ptc) Limited 2201 Interest of corporation controlled by you
Stellar Infinity Company Ltd. 2101 Beneficial owner
Sunrise Investment Advisors Limited 2201 Interest of corporation controlled by you
Zhong Huijuan 2307 Founder of a discretionary trust who can infl
Apex Medical Company Ltd. 2101 Beneficial owner

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines